1. Psoriasis

Category Archives: Psoriasis

Diabetic foot, Psoriasis, mood disorder – Remedy Hospital in Hyderabad – 6TV Sanjeevani – Video

Posted on by


Diabetic foot, Psoriasis, mood disorder - Remedy Hospital in Hyderabad - 6TV Sanjeevani
6TV Sanjeevani is a special program to create awareness on diseases which leads to health problems disturbing daily life. The safety measures, remedies to be taken for the diseases and the...

By: 6tv

See the original post:

Diabetic foot, Psoriasis, mood disorder - Remedy Hospital in Hyderabad - 6TV Sanjeevani - Video

DermaMed Psoriasis Kit – Rescue Balm and Nutrition for Troubled Skin – Video

Posted on by


DermaMed Psoriasis Kit - Rescue Balm and Nutrition for Troubled Skin
http://www.biologicalhealthgroup.com/product/dermamed-psoriasis-kit/ Provides a focused, two-step support program for managing psoriasis. Contains a powerful...

By: PDC BiologicalHealthGroup

See the original post here:

DermaMed Psoriasis Kit - Rescue Balm and Nutrition for Troubled Skin - Video

Novartis' plaque psoriasis drug candidate AIN457 gets FDA committee recommendation

Posted on by

PBR Staff Writer Published 21 October 2014

The US Food and Drug Administration's (FDA) Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) has approved Novartis' AIN457 (secukinumab), a selective interleukin-17A (IL-17A) inhibitor, to treat moderate-to-severe plaque psoriasis in adult patients.

The DODAC recommendation is based on the safety and efficacy outcomes from ten psoriasis Phase II/III clinical trials which included nearly 4,000 patients with moderate-to-severe plaque psoriasis.

Novartis Pharmaceuticals global head development Vas Narasimhan said moderate-to-severe psoriasis is a serious condition where patients suffer from skin lesions that cause itching, pain and scaling.

"There is a need for novel therapies as not all treatments are appropriate or effective in every patient," Narasimhan said.

"Today's recommendation is based on the efficacy and safety data put forth in our robust clinical trial program and brings us one step closer to delivering an innovative, new treatment option for people suffering from moderate-to-severe psoriasis. We look forward to working with the FDA as it finalizes its review."

The Phase III clinical program for secukinumab included four placebo-controlled pivotal trials which examined secukinumab 300mg and 150mg in patients with moderate-to-severe plaque psoriasis.

In these studies, secukinumab met all primary and key secondary endpoints, including Psoriasis Area and Severity Index (PASI) 75 and 90 and Investigator's Global Assessment modified 2011 (IGA mod 2011) 0/1 responses, showing significant skin clearance at Week 12.

The company submitted a Biologics License Application (BLA) for secukinumab to the FDA in October 2013 and the FDA action date is expected in early 2015.

View post:

Novartis' plaque psoriasis drug candidate AIN457 gets FDA committee recommendation

Mustard for leg cramps and psoriasis

Posted on by

Published: Tue, October 21, 2014 @ 12:00 a.m.

Q. My husband is disabled by osteoarthritis and psoriatic arthritis. He experienced frequent muscle cramping and was eating extra yellow mustard for relief.

His psoriasis was treated for years by a dermatologist. After a few weeks of taking large amounts of mustard, he noticed his psoriasis was greatly improved.

After his muscles stopped cramping, he stopped eating mustard. His psoriasis started returning. He has now resumed taking mustard this time for psoriasis.

A. Many readers have reported that a teaspoon or two of yellow mustard eases leg cramps, but you are the first to suggest that this condiment might be helpful for psoriasis.

Your story led us to do some digging in the medical literature. A mouse study published in China demonstrated that when mustard seed was fed to rodents, it suppressed psoriasislike inflammation (Journal of Southern Medical University, September 2013). Japanese scientists concluded that the results of their research provide a basis for mustard seed to be used as a promising intervention for psoriasis in the future (Journal of Dermatology, July 2013).

Your husbands experiment with mustard appears to confirm the preliminary research carried out in animals. Thanks for sharing his experience. Perhaps others will benefit from his discovery.

Q. Your column mentioned using pineapple or banana skin as a topical treatment for plantar warts. The treatment of choice (unfortunately not well known among family doctors or even dermatologists) may be the daily topical application of vitamin A.

Vitamin A can be bought in capsules in any drugstore. Puncture a capsule of the vitamin with a sharp needle. Each day, squeeze a drop or two of the vitamin A oil out of the capsule onto the wart and rub it in well.

Dr. Robert Garry reported 100 percent success within five months in 50 consecutive patients (New England Journal of Medicine, Oct. 14, 2004). I likewise had success with this treatment for a very stubborn plantar wart, although mine required applying the vitamin twice a day to get results.

Read the original here:

Mustard for leg cramps and psoriasis

Autoimmune form of Pneumonia is related to Psoriasis & Inflammation #41 – Video

Posted on by


Autoimmune form of Pneumonia is related to Psoriasis Inflammation #41
Autoimmune inflammatory sensitivity sometimes causes a form of pneumonia. Autoimmune pneumonia and psoriasis have the same cause;eating toxic foods like vinegar your family heritage never ate.

By: Psoriasis Channel

Continue reading here:

Autoimmune form of Pneumonia is related to Psoriasis & Inflammation #41 - Video

Yellow mustard for leg cramps and psoriasis

Posted on by

Q: My husband is disabled by osteoarthritis and psoriatic arthritis. He experienced frequent muscle cramping and was eating extra yellow mustard for relief.

His psoriasis was treated for years by a dermatologist. After a few weeks of taking large amounts of mustard, he noticed his psoriasis was greatly improved.

After his muscles stopped cramping, he stopped eating mustard. His psoriasis started returning. He has now resumed taking mustard this time for psoriasis.

A: Many readers have reported that a teaspoon or two of yellow mustard eases leg cramps, but you are the first to suggest that this condiment might be helpful for psoriasis.

Your story led us to do some digging in the medical literature. A mouse study published in China demonstrated that when mustard seed was fed to rodents, it suppressed psoriasislike inflammation (Journal of Southern Medical University, September 2013). Japanese scientists concluded that the results of their research provide a basis for mustard seed to be used as a promising intervention for psoriasis in the future (Journal of Dermatology, July 2013).

Your husbands experiment with mustard appears to confirm the preliminary research carried out in animals. Thanks for sharing his experience. Perhaps others will benefit from his discovery.

Q: Your column mentioned using pineapple or banana skin as a topical treatment for plantar warts. The treatment of choice (unfortunately not well known among family doctors or even dermatologists) may be the daily topical application of vitamin A.

Vitamin A can be bought in capsules in any drugstore. Puncture a capsule of the vitamin with a sharp needle. Each day, squeeze a drop or two of the vitamin A oil out of the capsule onto the wart and rub it in well.

Dr. Robert Garry reported 100 percent success within five months in 50 consecutive patients (New England Journal of Medicine, Oct. 14, 2004). I likewise had success with this treatment for a very stubborn plantar wart, although mine required applying the vitamin twice a day to get results.

No side effects have been reported. It just requires stubborn persistence.

Visit link:

Yellow mustard for leg cramps and psoriasis

psoriasis treated by Dr. Rajesh Khandelwal at Astha clinic (best treatment for psoriasis in India) – Video

Posted on by


psoriasis treated by Dr. Rajesh Khandelwal at Astha clinic (best treatment for psoriasis in India)
Visit our official site at http://www.asthaclinic.com/ like us on Facebook https://www.facebook.com/AsthaClinicajmer.

By: Dr Rajesh Khandelwal

More:

psoriasis treated by Dr. Rajesh Khandelwal at Astha clinic (best treatment for psoriasis in India) - Video

New Study Finds Link Between High Blood Pressure And Psoriasis

Posted on by

October 18, 2014

Chuck Bednar for redOrbit.com Your Universe Online

Patients with moderate to severe psoriasis are also more likely to have uncontrolled hypertension than those not suffering from the common skin condition, according to new research appearing in the October 15 online edition of the journal JAMA Dermatology.

Researchers from the University of Pennsylvania Perelman School of Medicine, Thomas Jefferson University in Philadelphia, and the National Heart, Lung, and Blood Institute (NHLBI) in Bethesda, Maryland examined the effect of psoriasis and its severity on blood pressure control among patients diagnosed as having hypertension.

The study authors recruited 1,322 patients with psoriasis and hypertension and 11,977 controls with hypertension but without psoriasis. They discovered a significant positive dose-response relationship between uncontrolled hypertension and psoriasis severity as objectively determined by the affected body surface area, meaning that the likelihood of uncontrolled blood pressure increased along with the severity of the skin condition.

As such, they reported that the likelihood of uncontrolled hypertension was the highest in patients suffering from moderate to severe psoriasis, defined by the researchers as three percent or more of the body surface area affected by the condition. The results held true even when controlled for age, sex, body mass index and other factors, and suggest the need for more effective blood pressure management in psoriasis patients.

Over the last several years, studies have shown that psoriasis, specifically severe psoriasis, is an independent risk factor for a variety of comorbidities, putting patients suffering with this common skin disease at an increased risk for other conditions such as heart attack and stroke, Junko Takeshita, co-first author of the new study, explained in a statement Thursday.

Knowing that psoriasis is tied to other health conditions, its vital that we have a better understanding of the systemic effects it has on other areas of the body so that we can more closely monitor these patients and provide better and preventative care, added Takeshita, a clinical instructor in the Penn Medicine department of dermatology.

For the purposes of the study, the researchers defined uncontrolled hypertension as blood pressure measured as at least 140/90, and examined data from a random sample of psoriasis patients included in a UK-based electronic medical database known as The Health Improvement Network (THIN). Takeshita said that the psoriasis diagnostic code in the THIN database had been validated through several research studies analyzing the condition.

To our knowledge, ours is the first study to evaluate the effect of objectively determined psoriasis severity on blood pressure control, Takeshita said. While the research has found a strong correlation between hypertension and psoriasis, it does not prove whether psoriasis could cause hypertension or whether the opposite is true. However, she noted that this new study is a good launching pad for future studies probing that issue.

Read more:

New Study Finds Link Between High Blood Pressure And Psoriasis

What Is The Definition Of Guttate psoriasis – Medical Dictionary Free Online Terms – Video

Posted on by


What Is The Definition Of Guttate psoriasis - Medical Dictionary Free Online Terms
Visit our website for text version of this Definition and app download. http://www.medicaldictionaryapps.com Subjects: medical terminology, medical dictionary, medical dictionary free download,...

By: Medical Dictionary Online

Original post:

What Is The Definition Of Guttate psoriasis - Medical Dictionary Free Online Terms - Video

Uncontrolled hypertension highest among patients with moderate-to-severe psoriasis

Posted on by

PUBLIC RELEASE DATE:

15-Oct-2014

Contact: Katie Delach katie.delach@uphs.upenn.edu 215-349-5964 The JAMA Network Journals @JAMA_current

Bottom Line: Patients with moderate and severe psoriasis have the greatest likelihood of uncontrolled hypertension compared to patients without psoriasis.

Author: Junko Takeshita, M.D., Ph.D., of the University of Pennsylvania Perelman School of Medicine, Philadelphia, and colleagues.

Background: Psoriasis is a chronic inflammatory disease of the skin and cardiovascular risk factors, including hypertension, are more prevalent among patients with psoriasis compared to those patients without. Previous studies suggest that psoriasis, especially when it is more severe, is associated with an increased risk of cardiovascular events such as heart attack, stroke and death.

How the Study Was Conducted: The authors examined the effect of psoriasis and its severity (which was measured by affected body surface area) on blood pressure control among patients with hypertension. The study included 1,322 patients with psoriasis and hypertension and 11,977 controls with hypertension but without psoriasis.

Results: The authors discovered a "dose-response relationship" between uncontrolled hypertension and psoriasis severity, which means the likelihood of uncontrolled hypertension increased with severity of the skin condition. Hence, the likelihood of uncontrolled hypertension was greatest among patients with moderate and severe psoriasis. Patients with psoriasis were equally as likely to be receiving antihypertensive treatment as were patients without psoriasis. The likelihood of treatment did not differ by the severity of the psoriasis.

Discussion: "Adding to the currently limited understanding of the effects of comorbid disease on hypertension, our findings have important clinical implications, suggesting a need for more effective management of blood pressure in patients with psoriasis, especially those with more extensive skin involvement [greater than or equal to 3 percent of body surface area affected]."

###

Read the rest here:

Uncontrolled hypertension highest among patients with moderate-to-severe psoriasis

Psoriasis Tied to Raised Risk of Uncontrolled Blood Pressure

Posted on by

Researchers suspect inflammation is the common denominator

WebMD News from HealthDay

By Amy Norton

HealthDay Reporter

WEDNESDAY, Oct. 15, 2014 (HealthDay News) -- People with more severe cases of psoriasis may be at increased risk of uncontrolled high blood pressure, a large study finds.

Researchers looking at over 13,000 adults in the United Kingdom found that those with severe psoriasis were 48 percent more likely to have poorly controlled blood pressure, versus people without the skin condition.

The findings, reported online Oct. 15 in the journal JAMA Dermatology, confirm an association between psoriasis and cardiovascular health. But the precise reasons are not clear, and a cause-and-effect link was not proven.

"We still don't fully understand why we see a higher prevalence of cardiovascular risk factors in people with psoriasis," said study leader Dr. Junko Takeshita, a clinical instructor of dermatology at the University of Pennsylvania in Philadelphia.

But, Takeshita said, chronic inflammation could be a common denominator.

People with psoriasis develop thick, scaly patches on their skin that are often itchy or sore. Experts believe the problem arises from an abnormal immune system attack on healthy skin cells -- a reaction that causes chronic inflammation. Chronic inflammation in the blood vessels is thought to contribute to high blood pressure ("hypertension"), heart disease and stroke.

Read the original:

Psoriasis Tied to Raised Risk of Uncontrolled Blood Pressure

Celgene's Otezla Encourages in Plaque Psoriasis at EADV – Analyst Blog

Posted on by

Celgene Corporation ( CELG ) presented encouraging data on its marketed drug, Otezla, for treating patients suffering from moderate-to-severe plaque psoriasis at the 23rd European Academy of Dermatology and Venereology (EADV) Congress in the Netherlands.

Celgene evaluated the effect of Otezla on health-related quality of life measures and work productivity/work limitation in the patient population through the analyses of the phase III ESTEEM clinical trial program. The program included two large pivotal randomized, placebo-controlled studies - ESTEEM 1 and ESTEEM 2. Analysis of the ESTEEM 2 study revealed a significant improvement in the health-related quality of life in patients treated with Otezla after 16 weeks compared to those in the placebo arm. Moreover, data from a pooled analysis of ESTEEM 1 and ESTEEM 2 at week 16 revealed significant increase in work productivity and improvement with respect to work limitations in patients treated with Otezla (30 mg: twice a day) compared to those in the placebo arm.

We remind investors that Otezla was cleared by the FDA last month for treating patients suffering from moderate-to-severe plaque psoriasis (read more: Celgene's Otezla Label Expanded to Include Plaque Psoriasis ). This was the second indication for which Otezla gained FDA approval. In March this year, Otezla was approved in the U.S. for treating adults with active psoriatic arthritis.

Otezla, the latest member of Celgene's product portfolio, contributed only $5 million to the biopharmaceutical company's top line in the second quarter of 2014. Nevertheless, we expect the drug to perform impressively in the third quarter, results of which will be reported on Oct 23.

Celgene carries a Zacks rank # 3 (Hold). Better-ranked stocks in the health care space include Shire ( SHPG ), Medivation ( MDVN ) and Regeneron Pharmaceuticals ( REGN ). Shire and Medivation sport Zacks Rank #1 (Strong Buy) while Regeneron is a Zacks Ranked #2 (Buy) stock.

CELGENE CORP (CELG): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

MEDIVATION INC (MDVN): Free Stock Analysis Report

SHIRE PLC-ADR (SHPG): Free Stock Analysis Report

To read this article on Zacks.com click here.

Read more from the original source:

Celgene's Otezla Encourages in Plaque Psoriasis at EADV - Analyst Blog

Novartis Releases Data on Secukinumab for Plaque Psoriasis – Analyst Blog

Posted on by

Novartis ( NVS ) announced positive data on pipeline candidate secukinumab (AIN457) from four phase III studies - ERASURE, FIXTURE, FEATURE and JUNCTURE.

The company is evaluating secukinumab for the treatment of moderate-to-severe plaque psoriasis.

Data from the studies showed that secukinumab 300 mg resulted in higher rates of clear to almost clear skin at week 12 as compared to placebo.

These data were presented at the European Association of Dermatology and Venereology Congress in Netherlands.

Data from the studies further confirm the results of the FIXTURE study wherein secukinumab has shown superiority to Amgen's ( AMGN ) Enbrel.

Last month, Novartis announced positive results from two phase III studies (FUTURE 1 and FUTURE 2) on secukinumab for the treatment of psoriatic arthritis (PsA). The studies evaluated the efficacy of secukinumab in PsA compared to placebo and assessed its safety and tolerability in the patients.

Both trials met their primary and key secondary endpoints. Results of the trial showed that treatment with secukinumab improved signs and symptoms of PsA along with improving peripheral joint disease and preventing joint damage as compared to placebo.

We note that Novartis had submitted secukinumab to regulatory bodies in both the U.S. and EU in 2013 for the treatment of psoriasis. The company is also evaluating secukinumab for the treatment of ankylosing spondylitis (AS) and rheumatoid arthritis (RA).

The successful development and commercialization of secukinumab for the treatment of psoriasis will further strengthen Novartis' dermatology portfolio. The company already has Xolair in its dermatology portfolio which is approved for the treatment of refractory chronic spontaneous urticaria (CSU) in the EU and is known as refractory chronic idiopathic urticaria (CIU) in the U.S.

The successful development and commercialization of the pipeline is important for the company as it faces generic competition for several key drugs such as Gleevec, Zometa and Diovan.

Continued here:

Novartis Releases Data on Secukinumab for Plaque Psoriasis - Analyst Blog


  1. Psoriasis